Stem Cell Transplantation 2012 Summary Slides SUM121ppt Location of Centers Participating in the CIBMTR 2012 SUM1222ppt Slide 2 Transplants SUM1223ppt Slide 3 Transplant Activity in the US ID: 425590
Download Presentation The PPT/PDF document "Current Uses and Outcomes of Hematopoiet..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation2012
Summary Slides
SUM12_1.pptSlide2
Location of Centers Participating
in the CIBMTR
2012
SUM12_22.ppt
Slide 2Slide3
Transplants
SUM12_23.ppt
Slide
3
Transplant Activity in the U.S.
1980-2011Slide4
SUM12_24.ppt
Allogeneic Stem Cell Sources
by Recipient Age
2001-2010
Age
£
20
yrs Age > 20 yrs
Slide
4
Transplants, %Slide5
SUM12_25.ppt
Autologous Stem Cell Sources
by Recipient Age, 2001-2010
Age
£
20
yrs Age
>
20 yrs
Slide
5
Transplants, %Slide6
SUM12_26.ppt
Trends in Transplants
by Type and Recipient Age
*
2001-2010
* Transplants for AML, ALL,
NHL, Hodgkin Disease, Multiple Myeloma
Slide
6
Transplants, %
Allogeneic
Transplants Autologous TransplantsSlide7
SUM12_27.ppt
Trends in Transplants
by Transplant Type and Recipient Age
*
1990-2010
* Transplants for AML, ALL,
NHL, Hodgkin Disease, Multiple Myeloma
Slide
7
Transplants,
%
Allogeneic
Transplants
Autologous TransplantsSlide8
Indications for Hematopoietic Stem Cell
Transplants in the United States, 2010
(Inflation factor: Auto=1.25 (80%),
Allo
=1.05 (95%), All Transplants)
SUM12_28.ppt
Slide
8
Number of TransplantsSlide9
Indications for Hematopoietic Stem Cell Transplants for Age £ 20yrs, in the U.S., 2010
(Inflation factor: Auto=1.25 (80%), Allo
=1.05 (95%), All Transplants)
SUM12_29.ppt
Slide 9
Number of TransplantsSlide10
SUM12_30.ppt
Allogeneic Transplants for Age
£
20yrs,
Registered with the CIBMTR, 1993-2010
-
by Donor Type and Graft Source -
Slide 10
Number of TransplantsSlide11
Allogeneic Transplants for Age
> 20yrs,
Registered with the CIBMTR, 1993-2010
- by Donor Type and Graft Source -
Slide
11
Number of Transplants
SUM12_31.pptSlide12
Unrelated Donor Stem Cell Sources
by Recipient Age
2001-2010
Age
£
20 yrs Age > 20 yrs
Slide
12
Transplants, %
SUM12_32.pptSlide13
Unrelated Cord Blood Transplants by Age
Registered with the CIBMTR
2001-2010
Slide
13
Number of Transplants
*
* Data incomplete
SUM12_33.pptSlide14
One-Year Survival, %
Slide 14
One-year Survival
by Year of Transplant, Donor and Age, Worldwide, 1997-2010
- In any remission, Acute Leukemia, CML or MDS-
SUM12_34.pptSlide15
100-day Mortality after
Autologous Transplants, 2010
Slide
15
Mortality,
%
SUM12_35.pptSlide16
100-day Mortality after
HLA-identical Sibling Transplants,
2010
Slide
16
Early Disease
Intermediate Disease
Advanced Disease
Chronic Phase
Accelerated Phase
Blast Phase
Other
Mortality,
%
SUM12_36.pptSlide17
100-day Mortality after
Unrelated Donor Transplants,
2008-2009
Slide
17
Early Disease
Intermediate Disease
Advanced Disease
Chronic Phase
Accelerated Phase
Blast Phase
Other
Mortality,
%
SUM12_37.pptSlide18
Causes of Death
after Transplants Done in
2009-2010
Autologous
Infection (7%)
Other (17%)
Organ Failure (3%)
New Malignancy (1
%)
Primary Disease
(72%)
Unrelated Donor
Infection
(18%)
Other
(18%)
Organ Failure (8%)
Primary Disease
(37%)
New Malignancy
(
1%)
GVHD (18%)
Slide
18
HLA-identical Sibling
Infection (13%)
Other
(16%)
Primary Disease
(49%)
GVHD (16%)
Organ Failure (5%)
New Malignancy (1%)
SUM12_38.pptSlide19
Allogeneic Transplants
Registered with the CIBMTR, 2001-2010
-
by Conditioning Regimen Intensity & Age
-
** Data incomplete
Slide
19
Number of Transplants
SUM12_39.pptSlide20
Allogeneic Transplants after Reduced-intensity Conditioning, by Donor Type,
Registered with CIBMTR
1998-2010
Slide
20
Number of Transplants
SUM12_40.pptSlide21
One-Year Survival, %
Slide 21
Percentage of Reduced Intensity Conditioning
Allo
-HCTs, Registered with CIBMTR, 1998-2010- by Year of Transplant & Disease -
SUM12_41.pptSlide22
Indications for Hematopoietic Stem Cell Transplants for Age ³ 5
0yrs, in the U.S., 2010
SUM12_42.ppt
Slide 22
Number of TransplantsSlide23
Allogeneic Transplants in the U.S.,
Registered with the CIBMTR, 2007-2011
-
by Donor Type
-
Slide 23
Transplants, %
SUM12_43.pptSlide24
SUM12_44.ppt
Hematopoietic Cell Transplant Comorbid Index of U.S. Transplant Recipients
by Group Age
2008-2011
Slide
24
Transplants, %Slide25
Probability of Survival after HLA-identical Sibling Donor Transplants for AML, 2000-2010- By Disease Status -
Years
0
2
6
1
3
4
5
Early
(N=7,210)
Intermediate
(N=1,906)
Advanced
(N=2,923)
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
SUM12_2.ppt
Slide
25
P < 0.0001Slide26
Probability of Survival after Unrelated Donor Transplants for AML, 2000-2010- By Disease Status -
Years
0
2
6
1
3
4
5
Early
(N=5,364)
Intermediate
(N=3,374)
Advanced
(N=3.702)
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
SUM12_3.ppt
Slide
26
P < 0.0001Slide27
Survival after HLA-identical Sibling Donor Transplants for AML, Age <20
yrs, 2000-2010- by Disease Status -
Years
0
2
6
1
3
4
5
Early
(N=1,292)
Intermediate
(N=268)
Advanced
(N=270)
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
SUM12_4.ppt
Slide
27
P < 0.0001Slide28
Probability of Survival after Autologous Transplants for AML, 2000-2010- by Disease Status -
Years
0
2
6
1
3
4
5
Early
(N=2,139)
Intermediate
(N=735)
Advanced
(N=152)
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
SUM12_5.ppt
Slide
28
P < 0.0001Slide29
Probability of Survival after Allogeneic Transplants for MDS, 2000-2010- by Disease Status and Donor Type -
SUM12_6.ppt
Slide
29
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
Early,
sibling donor (N=750)
Early,
unrelated
donor (N=890)
Advanced,
sibling donor (N=1,407)
Advanced,
unrelated donor (N=1,660)
P < 0.0001Slide30
Survival after HLA-identical Sibling Donor Transplants for ALL, Age < 20
yrs, 2000-2010- by Disease Status -
SUM12_7.ppt
Slide
30
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
P < 0.0001
Early
(N=849)
Intermediate
(N=1,203)
Advanced
(N=210)Slide31
Probability of Survival after Unrelated Donor Transplants for ALL, Age < 20
yrs, 2000-2010- By Disease Status -
SUM12_8.ppt
Slide
31
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
P
< 0.0001
Intermediate (N=2,034)
Advanced (N=289)
Early (N=977)Slide32
Survival after HLA-identical Sibling Donor Transplants for ALL, Age ³ 20
yrs, 2000-2010- By Disease Status -
Slide
32
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
P
< 0.0001
Intermediate (N=715)
Advanced (N=584)
Early (N=2,214)
SUM12_9.pptSlide33
Probability of Survival after Unrelated Donor Transplants for ALL, Age ³ 20
yrs, 2000-2010- By Disease Status -
Slide
33
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
P
< 0.0001
Intermediate (N=1,075)
Advanced (N=767)
Early (N=1,818)
SUM12_10.pptSlide34
Probability of Survival after HLA-identical Sibling Donor Transplants for CML, 1998-2010- By Disease Status and Transplant Year -
Slide
34
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
P
< 0.0001
CP, 1998-2000 (N=2,239)
AP, 1998-2000 (N=291)
CP
,
2001-2010
(N=2,498)
AP,
2001-2010
(N=360)
SUM12_11.pptSlide35
Survival after Autologous and HLA-matched Sibling Donor Hematopoietic Cell Transplants for CLL, 2000-2010-
by Donor Type and Conditioning Regimen Intensity -
Slide
35
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
P
< 0.0001
Autologous
transplant
(N=270)
Myeloablative
conditioning (N=450)
Reduced-intensity conditioning
(N=871)
SUM12_12.pptSlide36
Probability of Survival after Allogeneic Transplants for SAA, 2000-2010- By Donor Type and Age -
Slide
36
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
P
< 0.0001
£
20y, Sibling Donor
(
N=1,375)
>
20y, Sibling Donor
(
N=1,425)
£
20y, Unrelated
Donor
(
N=654)
>
20y, Unrelated
Donor
(
N=634)
SUM12_13.pptSlide37
Probability of Survival after Autologous Transplants for Hodgkin Disease, 2000-2010- By Disease Status -
Slide
37
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
P
< 0.0001
CR (N=2,907)
Not in CR, sensitive (N=3,832)
Not in CR, resistant (N=1,237)
SUM12_14.pptSlide38
Probability of Survival after Allogeneic Transplants for Hodgkin Disease, 2000-2010- By Conditioning Regimen and Donor Type -
Slide
38
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
P
= 0.226
Sibling Donor (N=356)
Unrelated Donor (N=205)
SUM12_15.pptSlide39
Survival after Autologous Transplants for Follicular Lymphoma, 2000-2010- By Disease Status -
Slide
39
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
P
< 0.0001
Sensitive (N=2,676)
Resistant (N=279)
SUM12_16.pptSlide40
Probability of Survival after Allogeneic and HLA-identical Sibling Transplants for Follicular Lymphoma, 2000-2010- By Disease Status -
Slide
40
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
P
= 0.002
Sensitive (N=840)
Resistant (N=212)
SUM12_17.pptSlide41
Probability of Survival after Autologous Transplants for Diffuse Large B-Cell Lymphoma, 2000-2010- By Disease Status -
Slide
41
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
P
< 0.0001
Sensitive (N=8,891)
Resistant (N=1,033)
SUM12_18.pptSlide42
Probability of Survival after HLA-identical Sibling Transplants for Diffuse Large B-Cell Lymphoma, 2000-2010- By Disease Status -
Slide
42
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
P
< 0.0001
Sensitive (N=503)
Resistant (N=219)
SUM12_19.pptSlide43
Probability of Survival after Transplants for Mantle Cell Lymphoma, 2000-2010- By Donor Type -
Slide
43
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
P
< 0.0001
Sibling donor (N=554)
Unrelated donor (N=389)
Autologous (3,173)
SUM12_20.pptSlide44
Probability of Survival after Transplants for Multiple Myeloma, 2000-2010- By Donor Type -
Slide
44
Years
0
2
6
1
3
4
5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Probability of Survival, %
P
< 0.0001
S
ibling Donor (N=892)
Unrelated donor (N=380)
Autologous (N27,979)
SUM12_21.ppt